Cyclerion Therapeutics (NASDAQ:KRSA) Earns Buy Rating from Analysts at TD Cowen

TD Cowen initiated coverage on shares of Cyclerion Therapeutics (NASDAQ:KRSA) in a report published on Monday morning, Marketbeat.com reports. The firm issued a buy rating on the stock.

Other analysts have also issued research reports about the company. UBS Group started coverage on Cyclerion Therapeutics in a report on Friday, September 11th. They set a “buy” rating and a $55.00 target price for the company. Zacks Research upgraded Cyclerion Therapeutics to a “hold” rating in a report on Wednesday, September 9th. Finally, Stifel Nicolaus began coverage on Cyclerion Therapeutics in a research report on Monday. They issued a “buy” rating and a $43.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $49.00.

Cyclerion Therapeutics Stock Down 2.6%

NASDAQ KRSA opened at $31.23 on Monday. Cyclerion Therapeutics has a 52-week low of $7.19 and a 52-week high of $59.36.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases of the central nervous system. The company has concentrated on therapies designed to influence the nitric oxide–soluble guanylate cyclase signaling pathway, which may play a role in neurological and other debilitating conditions.

Cyclerion’s lead development program was IW-6463, an oral, central nervous system-penetrant soluble guanylate cyclase stimulator investigated for potential use in neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis.